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CASE STUDY 
Navigating a Difficult Transition in Pulmonary Arterial Hypertension: 
A Clinical Case Study 
Tina Hyman, MSN, RN-BC; Michael Salinero, BSN, RN;  Javier Jimenez, MD, PhD, FACC;  
Margarita Pallares, MSN, APRN, AGACNP-BC; Maribel Matos , MSN, APRN, AANP-BC 
Over the past 20 years, Pulmonary Arterial Hypertension (PAH) patients and providers have seen an increase 
in options to treat PAH.  Currently, there are choices for the delivery of medications approved to treat patients with 
PAH where at one point the only option was intravenous (IV) therapy. This case study details the transition from 
IV Epoprostenol to oral Treprostinil for the treatment of a 53 year old female diagnosed with severe Pulmonary 
Arterial Hypertension whose quality of life became unbearable by the IV medication delivery route.  This patient 
was a synchronized swimmer in her youth and her passion for water activities continued throughout her short life.  
After her diagnosis of severe PAH, her life abruptly changed as she was placed on triple therapy, which consisted 
of an endothelin receptor antagonist (ERA), a phosphodiesterase-5 inhibitor (pde-5), and the IV epoprostenol.  The 
patient experienced severe side effects that negatively impacted her ability to resume her activities of daily life and 
swimming.  Although she remained hemodynamically stable on IV therapy, her poor quality of life and severe de-
pression convinced her cardiologist that transitioning to an oral treprostinil would be the only option for her surviv-
al.  At the time, there was a lack of clinical trials or guidelines to support the transition from IV to oral prostacy-
clins to follow, so an interdisciplinary team approach needed to be taken to ensure that the safety and efficacy of 
the transition would be maintained. 
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ABSTRACT 
BACKGROUND 
The World Health Organization has categorized 
Pulmonary Hypertension into five groups: Pulmonary 
Arterial Hypertension, Pulmonary Hypertension due to 
left heart disease, Pulmonary Hypertension due to lung 
disease, Pulmonary Hypertension due to chronic blood 
clots in the lungs, and Pulmonary Hypertension due to 
unknown causes (Pulmonary Hypertension Associa-
tion, 2019).  PAH is diagnosed during a right heart 
catheterization and is characterized by the remodeling, 
narrowing and elimination of pulmonary arteries 
caused by endothelial cell proliferation, inflammation 
of the vascular wall and fibrosis which elevates the 
pulmonary pressures  (Hambly, 2016 ). It is a rare but 
serious condition affecting as few as 5 in 1 million 
adults with a 5 year survival rate of just 37% as record-
ed in the 1980’s NIH registry (McLaughlin, 2013).  
The associated symptoms are disabling to the patient 
and include dyspnea, fatigue, syncope, and chest pain 
leading to premature death due to their risk for devel-
oping right ventricular failure (Hambly, 2016 ).  
      It was Aminorex (Fen/phen), an appetite suppres-
sant, which caused an epidemic of the disease in 1965 
which led to the withdrawal of Fen/Phen from the mar-
ket in 1997 (Anderson, 2016).  It wasn’t until the 
1990’s that a treatment care plan including warfarin in 
combination with high dose calcium channel blockers 
started being prescribed for the treatment of PH.  Then, 
a clinical trial demonstrated that the use of long-term 
intravenous (IV) prostacyclin improved the hemody-
namics and functional class in this patient population 
(McLaughlin, 2013).  Following the study of IV pros-
tacyclins, inhaled and oral prostacyclins were investi-
gated; in 2013, the Food and Drug Administration 
(FDA) approved the first oral prostacyclin for the treat-
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ment of PAH (Anderson, 2016).  The oral drug was in 
development for 17 years and offered another route of 
administration for patients requiring prostacyclin ther-
apy  (United Therapeutics, 2013). Currently, there are 
14 approved medications for the treatment of PH. At 
one point the treatment option for PH was exclusively 
IV therapy but now the delivery options have expand-
ed to include both oral and inhalation administration 
routes.   
     More oral and inhaled prostacyclins or prostacyclin 
analogs have become available in recent years. Recent-
ly successful transitions from IV prostacyclin to one of 
the oral/inhaled equivalents have been reported, but at 
the time of this report, there were no published guide-
lines to transition patients from IV epoprostenol to oral 
treprostinil to refer to. Although both drugs are similar, 
epoprostenol differs from treprostinil with its shorter 
half –life, no greater than six minutes, and the absence 
of an oral equivalent.  Both drugs, independently, have 
been shown to be effective in the treatment of pulmo-
nary hypertension (Saito, 2015).  
     The use of central lines to deliver prostacyclin ther-
apy comes with many expected side-effects as well as 
complications.  Flushing, sinus congestion, GI upset, 
diarrhea, generalized edema, insertion site discomfort, 
generalized pain, and headaches are the most common 
side effects which effects patient’s quality of life 
(Hanlon, 2017).  It is reasonable that patients, like the 
patient in this case study, who suffer with severe side 
effects, experience a decrease in quality of life.  The 
treatment regimen for each patient is highly individual-
ized according to the patient’s tolerance of each titra-
tion increase.  The following case study details the 
seven week transition schedule that was used to wean 
the patient off of IV onto an oral treprostinil and chal-
lenges the healthcare team had to overcome to help 
this patient achieve greater independence and better 
quality of life. 
CASE PRESENTATION 
A 53-year-old female diagnosed with severe Pul-
monary Arterial Hypertension by right heart catheteri-
zation in 2012. It is believed that this patient developed 
PAH by using the appetite suppressant Fen-Phen.  In 
2012 the patient was placed on triple therapy which 
included a phosphodiesterase inhibitor (PDE-5), an 
endothelin receptor antagonist (ERA), and IV epo-
prostenol.  The patient was referred to a PH specialist 
for further evaluation and treatment.  The patient expe-
rienced severe side-effects from the IV infusion in-
cluding: pronounced facial flushing, sinus congestion, 
GI upset, diarrhea, generalized edema, and headache. 
Other complaints included central catheter pain, short-
ness of breath on exertion, depression, and continuous 
oxygen dependence.  The patient remained medically 
stable on the IV therapy but due to the risk for line 
infection, safety, and diminished quality of life, the 
physician and patient decided to transition from the IV 
epoprostenol to oral treprostinil.  
Establishing a transition protocol from IV epo-
prostenol  to oral treprostinil in the absence of clear 
guidelines and in an outpatient setting was challenging.  
A health care team consisting of a pharmacist, nurses, 
cardiologist, pulmonologist, and drug manufacturer 
RN representative were all consulted and contributed 
to the patient’s titration schedule. Each specialty dis-
cussed treatment options and potential complications.  
Once the choice of oral medication was identified, a 
clinical pharmacist assembled a transition schedule 
using contributions given by the planning team and 
limited data which was available on the topic. The 
weekly titrations were performed under the close ob-
servation of the cardiologist whether in the medical 
office, at home with the drug RN representative, or in 
the outpatient clinic which specializes in PH.  The pa-
tient’s physical and mental status were discussed, eval-
uated, and well documented during the seven week 
period.  A slow transition schedule was used to accom-
modate the patient and secure her safety.  The patient 
was seen at the cardiologist office as well as the heart 
failure outpatient clinic alternating weekly and had 
phone access to all members of the team 24/7.  The 
dosing schedule using dual therapy during the seven 
day titration period is shown in Table 1. The patient 
was getting 20ng/kg/min of the IV epoprostenol prior 
to the titration.  
DISCUSSION 
This case represents a difficult but successful tran-
sition from intravenous epoprostenol to oral treprosti-
nil despite the lack of guidelines. The patient was able 
to transition to oral treprostinil 14 mg/p.o./daily and 
stayed medically stable. Furthermore, her exercise 
tolerance increased and she was able to resume activi-
ties, such as swimming and other hobbies that were 
prohibited once IV therapy had been initiated improv-
ing her quality of life and renewing her sense of hope. 
Since this case study, there has been many successful 
week-long transitions published with improved exer-
cise tolerance and patient outcomes (Gleason, 2015).  
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Similarly, there have been successful, safe, and cost 
efficient transitions from IV epoprostenol to oral PH 
prostacyclin therapies in the outpatient setting (Morris 
KL, 2018).  However, at the time of this case, the 
healthcare team had to work very careful and diligently 
regardless of the lack of treatment guidelines, to make    
a quick decision to provide this patient with a mean-
ingful and improved quality of life.  
Currently, there are published criteria that identify 
ideal candidates for IV to oral transitions.  These pa-
tients have to show hemodynamic, clinical, and physi-
ological signs of stability in order to achieve a success-
ful transition (Coons, 2016; Sofer, 2017). This case 
report does not provide data on the long-term success 
from an IV epoprostenol to oral treprostinil transition, 
however, this patient was able to transition and main-
tain her physiological status as well as report a better 
quality of life. 
Table 1 





Oral Treprostinil Dose 







morning  0.125 mg (use 0.125 mg tab) 
noon  0.125 mg (use 0.125 mg tab) 





morning  0.5mg  (2  tabs of 0.25mg tab) 
noon  0.5 mg (2  tabs of 0.25mg tab) 
evening  0.5 mg (2  tabs of 0.25mg tab) 




morning 1mg (4 tabs of 0.25mg tab)  
noon 1 mg  (4  tabs of 0.25mg tab) 





morning 2mg  (2 tabs of 1mg tab) 
noon  2 mg (2 tabs of 1mg tab) 





morning:  3.5 mg  (2.5 mg tab+1 mg tab) 
noon:  3.0 mg (2.5 mg tab+0.5 mg tab) 
evening:  3.5mg (2.5 mg+1 mg tab ) 
10 mg/po/day 
Week 6  
(Cardiologist office) 
1.5 ng/kg/min 
morning: 4 mg  (2.5 mg tab+1 mg tab +0.25 tab+0.25 tab) 
noon:  4 mg (2.5 mg tab+1 mg tab+0.25t ab+0.25 tab) 





morning: 4 mg (2.5 mg tab+1 mg tab+2 tabs of 0.25mg tab) 
noon:  5 mg (2 tabs of 2.5mg) 
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     This case study demonstrates that making sound 
treatment decisions can be difficult at times but the 
goal of the treatment can be accomplished with strong 
collaboration, compassion, and respect for the individ-
ual’s quality of life. The transition incorporated the 
expertise of the multidisciplinary team including the 
pharmacist, nurses, cardiologist, pulmonologist, and 
drug manufacturer’s RN representative in order to es-
tablish a safe plan of care that addressed the individual 
needs of this patient. The best decision-making for 
medical treatments is made when healthcare providers 
take into account patients’ quality of life.  
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